N-acetylglucosamine inhibits inflammation and neurodegeneration markers in multiple sclerosis: a mechanistic trial
https://jneuroinflammation.biomedcentra ... 23-02893-9
Results
Prior to GlcNAc therapy, high serum levels of the inflammatory cytokines IFNγ, IL-17 and IL-6 associated with reduced baseline levels of a marker of endogenous serum GlcNAc. Oral GlcNAc therapy was safe, raised serum levels and modulated N-glycan branching in lymphocytes.
Glatiramer acetate reduces TH1, TH17 and B cell activity as well as sNfL, yet the addition of oral GlcNAc dose-dependently lowered serum IFNγ, IL-17, IL-6 and NfL. Oral GlcANc also dose-dependently reduced serum levels of the anti-inflammatory cytokine IL-10, which is increased in the brain of MS patients. 30% of treated patients displayed confirmed improvement in neurological disability, with an average EDSS score decrease of 0.52 points.
Conclusions
Oral GlcNAc inhibits inflammation and neurodegeneration markers in MS patients despite concurrent immunomodulation by glatiramer acetate. Blinded studies are required to investigate GlcNAc’s potential to control residual brain inflammation, myelin repair and neurodegeneration in MS.
Anti inflammation
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1254 Views
-
Last post by NHE
-
- 0 Replies
- 1422 Views
-
Last post by frodo
-
- 6 Replies
- 1790 Views
-
Last post by DIM
-
- 2 Replies
- 3193 Views
-
Last post by frodo
-
- 0 Replies
- 1649 Views
-
Last post by NHE
-
- 0 Replies
- 1418 Views
-
Last post by frodo
-
- 0 Replies
- 12045 Views
-
Last post by NHE
-
- 0 Replies
- 2006 Views
-
Last post by NHE
-
- 0 Replies
- 2638 Views
-
Last post by frodo